SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending amid renewed optimism driven by China's extension of EV trade-in subsidies into 2026 and robust Q4 sales forecasts, including potential record December deliveries. The community is actively discussing strong operational performance and strategic advancements like battery swapping, with many bullish investors accumulating shares on expectations of profitability. However, some continue to voice concerns over persistent market manipulation impacting the stock's valuation despite positive developments.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending due to the FDA issuing a Complete Response Letter for its relacorilant drug, triggering significant market volatility. The community is sharply divided, with some investors calling for further decline and celebrating put option gains, while others view the sell-off as an overreaction. Many highlight the company's existing profitable drug and argue that the FDA's acknowledgment of positive trial data suggests a path forward, creating a potential dip-buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IMAX Corp. (IMAX) announced Tuesday that it has expanded its senior secured revolving credit facility to $375 million, up from $300 million.The cinema technology company's larger and more flexible credit line marks a&nbsp;massive boost to its financial toolkit.&nbsp;Despite the news,&nbsp;<a href="https://stocktwits.com/symbol/IMAX">IMAX stock</a> inched lower by 0.2% on Tuesday afternoon.The deal features an option that may boost the borrowing limit to a minimum of $515 million, subject to lender consent.&nbsp;This credit facility extends until 2030 and offers reduced interest expenses compared to the previous agreement. The agreement was coordinated by Wells Fargo Securities, LLC, alongside six other lenders.The revised financing package provides IMAX with greater flexibility in a competitive and capital-intensive market. The company stated that the expanded credit facility will support a range of objectives, including ongoing operations, expansion of its global footprint, and potential refinancing of current liabilities.&nbsp;"As we expand our network and content portfolio, this facility provides us with additional flexibility in executing our priorities and optimizing our capital structure,” said CEO Rich Gelfond.&nbsp;In June, the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/imax-expands-stock-buyback-program-by-100-million/chlgPOTRRGR">intensified</a> its effort to reward shareholders by adding $100 million to its existing stock repurchase program.The credit upgrade arrives as IMAX continues to broaden its international theater network and strengthen its technology platform.High-end theaters have significantly&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/imax-gains-ground-on-record-year-target/ch8cmZwR5NI">contributed&nbsp;</a>to increasing the company’s box office market share.IMAX currently operates around 1,700 screens, with about 400 in North America. The company’s film schedule through 2026 features titles like Disney’s ‘Avatar: Fire and Ash,’ Marvel’s ‘Fantastic Four: First Steps,’ and Amazon.com Inc.’s (AMZN) ‘Project Hail Mary.’On Stocktwits, retail sentiment towards IMAX remained in ‘bullish’ territory with ‘high’ message volume levels.<figure class="image"><img style="aspect-ratio:804/95;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_15_at_1_41_21_PM_png_d75cb55c89.webp" alt="IMAX’s Sentiment Meter and Message Volume as of 01:45 p.m. ET on July 15, 2025 | Source: Stocktwits" width="804" height="95"><figcaption>IMAX’s Sentiment Meter and Message Volume as of 01:45 p.m. ET on July 15, 2025 | Source: Stocktwits</figcaption></figure>&nbsp;IMAX stock has gained over 8% in 2025 and more than 61% in the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/meta-faces-renewed-eu-scrutiny-over-ad-consent-practices/ch8QOcnR5Fx">Meta Faces Renewed EU Scrutiny Over Ad Consent Practices: Retail Keeps Neutral Ground</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the IMAX logo is seen displayed on a smartphone. 

IMAX’s New Credit Deal Gives More Firepower Through 2030: Retail Echoes Confidence

IMAX Corporation has increased its senior secured revolving credit facility from $300 million to $375 million, with potential expansion to $515 million.

Equity

IMAX Corporation has increased its senior secured revolving credit facility from $300 million to $375 million, with potential expansion to $515 million.


IMAX Corp. (IMAX) is reportedly expected to hit its highest annual performance yet, driven by strong ticket sales, increasing appetite for high-end cinema experiences, and a broad international growth plan.According to a CNBC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/07/11/imax-hollywood-box-office-rebound.html">report</a>,&nbsp;premium-format theaters have played a major role in boosting the company’s share of the box office.&nbsp;It noted that&nbsp;Apple Inc.’s (AAPL)&nbsp;‘F1: The Movie’ brought in close to $300 million worldwide within its first 10 days, with more than 20% of that total coming from IMAX showings.&nbsp;Following the report,&nbsp;<a href="https://stocktwits.com/symbol/IMAX">IMAX stock</a> traded 2.6% higher on Friday afternoon.The report added that,&nbsp;in the U.S. and Canada, IMAX venues generated 25% of the film’s domestic revenue, despite making up less than 1% of all movie screens globally. Major releases are increasingly opting for IMAX presentation, with titles like Warner Bros' ‘Sinners’ and Paramount’s ‘Mission: Impossible – The Final Reckoning’ earning over 20% of their total revenue from IMAX showings.&nbsp;It said&nbsp;the format’s enhanced visuals and custom camera technology have helped draw larger audiences and higher ticket revenue.&nbsp;The company’s CEO, Rich Gelfond, highlighted that eight films in a row were shot using IMAX cameras, emphasizing that more filmmakers are endorsing the format.&nbsp;IMAX currently operates around 1,700 screens, with about 400 in North America, and has deals in place to install 500 additional theaters worldwide, the report stated.In the fourth-quarter (Q4) earnings call, Gelfond projected $1.2 billion in revenue for 2025, a potential all-time high.In May, the company expanded its collaboration with&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regal-and-imax-expand-partnership/ch0cu8RRb83">Regal Cinemas</a> by launching four additional IMAX with Laser theaters in key metropolitan regions across the U.S.The release calendar through 2026 includes movies such as Disney’s ‘Avatar: Fire and Ash,’ Marvel’s ‘Fantastic Four: First Steps,’ Amazon.com Inc.'s (AMZN) ‘Project Hail Mary’” and new entries in the Star Wars, Toy Story, and Shrek franchises.Recently, Eric Handler, an analyst at Roth Capital, had said that IMAX’s worldwide box office performance is rebounding strongly and could match or exceed its $1.2 billion forecast for 2025, as per TheFly.On Stocktwits, retail sentiment toward IMAX jumped to ‘bullish’ from ‘bearish’ territory the previous day.<figure class="image"><img style="aspect-ratio:972/123;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_134746_png_a2b7a34708.webp" alt="IMAX’s Sentiment Meter and Message Volume as of 02.00 p.m. ET on July 11, 2025 | Source: Stocktwits" width="972" height="123"><figcaption>IMAX’s Sentiment Meter and Message Volume as of 02.00 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>IMAX stock has gained over 4% in 2025 and over 54% in the last 12 months.Also See:&nbsp;Microsoft Investors Demand Oversight On AI Use In Gaza, Questioning Human Rights Due DiligenceFor updates and corrections, email newsroom[at]stocktwits[dot]com.

A billboard near Hollywood & Highland promotes the new Tom Cruise movie 'Mission: Impossible The Final Reckoning' on May 23, 2025 in Hollywood, California. 

IMAX Gains Ground On Record Year Target As Blockbusters Reportedly Drive Market Share Surge – Retail Echoes Confidence

IMAX’s premium format is driving box office growth, with blockbusters like “F1: The Movie” boosting market share. Global expansion, content demand, and higher ticket prices fuel an optimistic outlook.

IMAX Corporation (IMAX) has announced an expansion of its partnership with movie theater chain Regal Cinemas to introduce four new IMAX with Laser locations in major U.S. metropolitan areas.&nbsp;The initiative aims to enhance the cinematic experience for moviegoers by incorporating laser projection technology into its theaters.IMAX’s latest theater additions will launch in prominent, high-traffic areas, such as the L.A. LIVE complex in downtown Los Angeles, Regal Greenway Grand Palace in Houston, Virginia Gateway in Gainesville, and Regal Sherman Oaks in Los Angeles.&nbsp;Each location is slated to deliver an upgraded cinematic experience with 70mm projection systems and 80-foot screens ranked among the largest in their metropolitan regions.“Passionate moviegoing audiences in major metropolitan areas fuel our growth, and we’re excited to expand our partnership with Regal Cineworld and give our fans even more ways to experience it in IMAX,” said IMAX CEO Rich Gelfond.IMAX 70mm film offers the highest possible resolution in cinema, captured exclusively using IMAX film cameras to achieve up to 18K resolution in each frame.&nbsp;Films shot in this specialized format are projected through IMAX 70mm film projectors, a unique system that can only be found in 30 locations worldwide.&nbsp;Recent titles filmed with IMAX cameras and showcased in 70mm include “Oppenheimer,” “Sinners,” and the 10th-anniversary re-release of “Interstellar.”&nbsp;The new IMAX locations will feature IMAX with Laser, the latest in entertainment technology, offering superior image quality, precise audio, and brighter, higher-resolution visuals.&nbsp;The deal also includes plans to renew 33 current Regal IMAX venues nationwide, along with completing ten IMAX with Laser system upgrades previously scheduled for 2025.&nbsp;On Stocktwits, retail sentiment around IMAX stayed in ‘bearish’ territory.<figure class="image"><img style="aspect-ratio:632/72;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_19_110329_png_4e5cc7c446.webp" alt="IMAX's Sentiment Meter and Message Volume as of 11:00 a.m. ET on May 19, 2025 | Source: Stocktwits" width="632" height="72"><figcaption>IMAX's Sentiment Meter and Message Volume as of 11:00 a.m. ET on May 19, 2025 | Source: Stocktwits</figcaption></figure>IMAX stock has gained over 5% in 2025 and 59% in the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/google-quietly-tests-discover-on-desktop-for-select-users-ahead-of-i-o-conference/ch0csSoRbFy">Google Quietly Tests Discover On Desktop For Select Users Ahead Of I/O Conference</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

General views of the IMAX Corporation headquarters on October 15, 2020 in Playa Vista, California. (Photo by AaronP/Bauer-Griffin/GC Images)

Regal, IMAX Enhance Cinematic Experience with New Laser Projection Installations: Retail Yet To React 

The new IMAX with Laser locations in major U.S. cities will feature advanced 70mm projection systems and enhanced visuals.

BOUT
Innovator ETFs Trust - Innovator IBD(R) Breakout Opportunities ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BOUT News

BOUTInnovator ETFs Trust - Innovator IBD(R) Breakout Opportunities ETF